caffeine has been researched along with Epilepsy in 61 studies
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "The relationship between caffeine, seizures, epilepsy, and anti-seizure drugs is not fully understood." | 9.01 | The Use of Caffeine by People with Epilepsy: the Myths and the Evidence. ( Bauer, PR; Sander, JW, 2019) |
| "PubMed was searched for studies assessing the effects of caffeine on seizure susceptibility, epilepsy, and drug interactions in people and in animal models." | 8.98 | Caffeine and seizures: A systematic review and quantitative analysis. ( Bauer, PR; Sander, JW; Schuitema, I; van Koert, RR; Visser, GH, 2018) |
| "Clinical reports have shown that some antihistamines, such as ketotifen, occasionally produced seizures, especially in pre-school age children or young patients with epilepsy." | 7.78 | The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats. ( Kanda, T; Takizawa, F; Tamura, T; Yamada, K, 2012) |
| "Seizures and epilepsy are associated with significant disability and substantial treatment costs, yet little is known about primary prevention." | 5.36 | A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II. ( Bromfield, EB; Dworetzky, BA; Kang, JH; Townsend, MK, 2010) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "The relationship between caffeine, seizures, epilepsy, and anti-seizure drugs is not fully understood." | 5.01 | The Use of Caffeine by People with Epilepsy: the Myths and the Evidence. ( Bauer, PR; Sander, JW, 2019) |
| "PubMed was searched for studies assessing the effects of caffeine on seizure susceptibility, epilepsy, and drug interactions in people and in animal models." | 4.98 | Caffeine and seizures: A systematic review and quantitative analysis. ( Bauer, PR; Sander, JW; Schuitema, I; van Koert, RR; Visser, GH, 2018) |
| "Clinical reports have shown that some antihistamines, such as ketotifen, occasionally produced seizures, especially in pre-school age children or young patients with epilepsy." | 3.78 | The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats. ( Kanda, T; Takizawa, F; Tamura, T; Yamada, K, 2012) |
| " Apart from the hyponatremia due to water intoxication the convulsions can be potentiated by the high dose of caffeine and aspartame from the diet coke." | 3.74 | Seizures and hyponatremia after excessive intake of diet coke. ( De Cauwer, HG; Merlevede, K; Mortelmans, LJ; Van Loo, M, 2008) |
| "The use of cocaine is associated with the occurrence of seizures." | 3.71 | Psychostimulants and epilepsy. ( Albano, C; Zagnoni, PG, 2002) |
| "Children due to receive carbamazepine for epilepsy were recruited into the study." | 3.70 | Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. ( Choonara, I; Parker, AC; Preston, T; Pritchard, P, 1998) |
| "Carbamazepine (CBZ) is known to have beneficial effects in the treatment of epilepsies and in the prophylaxis of affective disorders." | 3.68 | Calcium-antagonistic effects of carbamazepine in epilepsies and affective psychoses. ( Bingmann, D; Düsing, R; Grunze, H; Liu, Z; Mayer, A; Schirrmacher, K; Walden, J, 1993) |
| "The present study evaluates effect of pharmacokinetic interaction between caffeine (300 mg) in three divided doses with sodium valproate (400 mg) and carbamazepine (200 mg) given as single doses, in normal human volunteers, using a open cross over design." | 2.69 | Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers. ( David, J; Joseph, T; Kulkarni, C; Vaz, J, 1998) |
| "Seizures and epilepsy are associated with significant disability and substantial treatment costs, yet little is known about primary prevention." | 1.36 | A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II. ( Bromfield, EB; Dworetzky, BA; Kang, JH; Townsend, MK, 2010) |
| "Caffeine is a mixed adenosine receptor antagonist, therefore its effects could be due to a different action on adenosine receptor subtypes; an additional mechanism of action cannot be excluded." | 1.33 | Biphasic effect of chronic postnatal caffeine treatment on cortical epileptic afterdischarges during ontogeny in rats. ( Kubová, H; Mares, P; Tchekalarova, J, 2006) |
| "The grave course of epilepsy is associated with a decrease of the LCBF on the side of the focus." | 1.28 | [Changes in cerebral blood circulation and their correction in the interparoxysmal period of epilepsy]. ( Shestakov, VV; Shutov, AA, 1990) |
| "Phenytoin treatment may impair the validity of the caffeine liver function test." | 1.28 | Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. ( Büchsel, R; Kohl, D; Kreiten, K; Matern, S; Wietholtz, H; Zysset, T, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (36.07) | 18.7374 |
| 1990's | 13 (21.31) | 18.2507 |
| 2000's | 10 (16.39) | 29.6817 |
| 2010's | 14 (22.95) | 24.3611 |
| 2020's | 2 (3.28) | 2.80 |
| Authors | Studies |
|---|---|
| Asadi-Pooya, AA | 1 |
| Zeraatpisheh, Z | 1 |
| Rostaminejad, M | 1 |
| Damabi, NM | 1 |
| Di Rocco, M | 1 |
| Galosi, S | 1 |
| Follo, FC | 1 |
| Lanza, E | 1 |
| Folli, V | 1 |
| Martire, A | 1 |
| Leuzzi, V | 1 |
| Martinelli, S | 1 |
| Schaf, J | 1 |
| Damstra-Oddy, J | 1 |
| Williams, RSB | 1 |
| van Koert, RR | 1 |
| Bauer, PR | 2 |
| Schuitema, I | 1 |
| Sander, JW | 2 |
| Visser, GH | 1 |
| Rubi, L | 1 |
| Schandl, U | 1 |
| Lagler, M | 1 |
| Geier, P | 1 |
| Spies, D | 1 |
| Gupta, KD | 1 |
| Boehm, S | 1 |
| Kubista, H | 1 |
| Tchekalarova, J | 3 |
| Kubová, H | 3 |
| Mareš, P | 3 |
| Turan, MI | 1 |
| Tan, H | 1 |
| Cetin, N | 1 |
| Suleyman, H | 2 |
| Cayir, A | 1 |
| Chrościńska-Krawczyk, M | 2 |
| Radzik, I | 1 |
| Miziak, B | 1 |
| Czuczwar, SJ | 2 |
| Shen, HY | 1 |
| Li, T | 1 |
| Boison, D | 2 |
| Dworetzky, BA | 1 |
| Bromfield, EB | 1 |
| Townsend, MK | 1 |
| Kang, JH | 1 |
| Borekci, B | 1 |
| Ingec, M | 1 |
| Yilmaz, M | 1 |
| Kukula, O | 1 |
| Karaca, M | 1 |
| Hacimuftuoglu, A | 1 |
| Halici, Z | 1 |
| Jargiełło-Baszak, M | 1 |
| Wałek, M | 1 |
| Tylus, B | 1 |
| Lusardi, TA | 1 |
| Lytle, NK | 1 |
| Szybala, C | 1 |
| Yamada, K | 1 |
| Takizawa, F | 1 |
| Tamura, T | 1 |
| Kanda, T | 1 |
| Angehagen, M | 1 |
| Margineanu, DG | 2 |
| Ben-Menachem, E | 1 |
| Rönnbäck, L | 1 |
| Hansson, E | 1 |
| Klitgaard, H | 2 |
| KETZ, E | 1 |
| BOROFFKA, A | 1 |
| LUSTIG, B | 1 |
| EZIMA, I | 1 |
| IMAI, T | 1 |
| EYSOLD, R | 1 |
| MOELLHOFF, G | 1 |
| REMEZOVA, ES | 1 |
| SAFONOVA, SA | 1 |
| CHAO, NT | 1 |
| LI, PJ | 1 |
| JUNOD, JP | 1 |
| MARTIN, F | 1 |
| Uzbay, TI | 1 |
| Kayir, H | 1 |
| Ceyhan, M | 1 |
| Schmidt, B | 1 |
| Roberts, RS | 1 |
| Davis, P | 1 |
| Doyle, LW | 1 |
| Barrington, KJ | 1 |
| Ohlsson, A | 1 |
| Solimano, A | 1 |
| Tin, W | 1 |
| Mortelmans, LJ | 1 |
| Van Loo, M | 1 |
| De Cauwer, HG | 1 |
| Merlevede, K | 1 |
| Neyraut-Sutterman, MT | 1 |
| Harrison, A | 1 |
| Gerlach, J | 1 |
| Moraidis, I | 2 |
| Bingmann, D | 4 |
| Walden, J | 1 |
| Grunze, H | 1 |
| Mayer, A | 1 |
| Düsing, R | 1 |
| Schirrmacher, K | 1 |
| Liu, Z | 1 |
| Bonnet, U | 1 |
| Francis, A | 1 |
| Fochtmann, L | 1 |
| De Sarro, A | 1 |
| Grasso, S | 1 |
| Zappala, M | 1 |
| Nava, F | 1 |
| De Sarro, G | 1 |
| Tran, A | 1 |
| Rey, E | 1 |
| Pons, G | 1 |
| Rousseau, M | 1 |
| d'Athis, P | 1 |
| Olive, G | 1 |
| Mather, GG | 1 |
| Bishop, FE | 1 |
| Wurden, CJ | 1 |
| Labroo, R | 1 |
| Trager, WF | 1 |
| Kunze, KL | 1 |
| Thummel, KE | 1 |
| Vincent, JC | 1 |
| Gillardin, JM | 1 |
| Lepage, F | 1 |
| Levy, RH | 1 |
| Parker, AC | 1 |
| Pritchard, P | 1 |
| Preston, T | 1 |
| Choonara, I | 1 |
| Vaz, J | 1 |
| Kulkarni, C | 1 |
| David, J | 1 |
| Joseph, T | 1 |
| Dzhala, V | 1 |
| Desfreres, L | 1 |
| Melyan, Z | 1 |
| Ben-Ari, Y | 1 |
| Khazipov, R | 1 |
| Jin, W | 1 |
| Sugaya, A | 1 |
| Tsuda, T | 1 |
| Ohguchi, H | 1 |
| Sugaya, E | 1 |
| Hashiguchi, W | 1 |
| Nagatomo, I | 1 |
| Akasaki, Y | 1 |
| Uchida, M | 1 |
| Tominaga, M | 1 |
| Takigawa, M | 1 |
| Lara, DR | 1 |
| Schmidt, AP | 1 |
| Frizzo, ME | 1 |
| Burgos, JS | 1 |
| Ramírez, G | 1 |
| Souza, DO | 1 |
| Zagnoni, PG | 1 |
| Albano, C | 1 |
| Shutov, AA | 2 |
| Pleshkova, NM | 1 |
| Shestakov, VV | 2 |
| Pozdniakov, VS | 1 |
| Dudkin, AO | 1 |
| Lehmenkühler, A | 1 |
| Speckmann, EJ | 1 |
| Bologa, M | 1 |
| Tang, B | 1 |
| Klein, J | 1 |
| Tesoro, A | 1 |
| Koren, G | 1 |
| Wietholtz, H | 1 |
| Zysset, T | 1 |
| Kreiten, K | 1 |
| Kohl, D | 1 |
| Büchsel, R | 1 |
| Matern, S | 1 |
| Frank, C | 2 |
| Sagratella, S | 2 |
| Benedetti, M | 2 |
| Scotti de Carolis, A | 2 |
| Maitre, M | 1 |
| Chesielski, L | 1 |
| Lehmann, A | 1 |
| Kempf, E | 1 |
| Mandel, P | 1 |
| Zappoli, R | 1 |
| Papini, M | 1 |
| Brunia, CH | 1 |
| Buyze, G | 1 |
| Rupollo, W | 2 |
| Shmilovich, LA | 1 |
| Poliak, AI | 1 |
| Hess, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| Multicenter, Comparative, Randomized, Open Trial to Evaluate Efficacy and Safety of Levetiracetam Versus Carbamazepine in Post Stroke Late Onset Crisis[NCT00542802] | Phase 3 | 630 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
6 reviews available for caffeine and Epilepsy
| Article | Year |
|---|---|
Caffeinated drinks, fruit juices, and epilepsy: A systematic review.
Topics: Caffeine; Coffee; Epilepsy; Fruit and Vegetable Juices; Humans | 2022 |
Dictyostelium discoideum as a pharmacological model system to study the mechanisms of medicinal drugs and natural products.
Topics: Animals; Anti-Infective Agents; Bacterial Infections; Biological Products; Bipolar Disorder; Caffein | 2019 |
Caffeine and seizures: A systematic review and quantitative analysis.
Topics: Animals; Anticonvulsants; Caffeine; Central Nervous System Stimulants; Drug Interactions; Epilepsy; | 2018 |
The Use of Caffeine by People with Epilepsy: the Myths and the Evidence.
Topics: Animals; Anticonvulsants; Caffeine; Central Nervous System Stimulants; Epilepsy; Humans; Seizures | 2019 |
Safety considerations for patients with epilepsy taking antiepileptic drugs alongside caffeine or other methylxanthine derivatives.
Topics: Aminophylline; Animals; Anticonvulsants; Caffeine; Coffee; Drug Interactions; Epilepsy; Humans; Theo | 2014 |
Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data.
Topics: Animals; Anticonvulsants; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Drug | 2011 |
2 trials available for caffeine and Epilepsy
| Article | Year |
|---|---|
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Influence of caffeine on pharmacokinetic profile of sodium valproate and carbamazepine in normal human volunteers.
Topics: Anticonvulsants; Caffeine; Carbamazepine; Cross-Over Studies; Drug Interactions; Epilepsy; Humans; M | 1998 |
53 other studies available for caffeine and Epilepsy
| Article | Year |
|---|---|
Phenotypic Assessment of Pathogenic Variants in
Topics: Animals; Caenorhabditis elegans; Caffeine; Epilepsy; GTP-Binding Proteins; Mutation | 2023 |
Raised activity of L-type calcium channels renders neurons prone to form paroxysmal depolarization shifts.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2013 |
Effects of caffeine on cortical epileptic afterdischarges in adult rats are modulated by postnatal treatment.
Topics: Aging; Animals; Caffeine; Central Nervous System Stimulants; Cerebral Cortex; Disease Models, Animal | 2013 |
Effects of thiamine and thiamine pyrophosphate on epileptic episode model established with caffeine in rats.
Topics: Animals; Brain; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response R | 2014 |
A novel mouse model for sudden unexpected death in epilepsy (SUDEP): role of impaired adenosine clearance.
Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Adenosine Kinase; Animals; Caffeine; Cause of De | 2010 |
A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II.
Topics: Adult; Age Distribution; Alcohol Drinking; Caffeine; Epilepsy; Female; Health Status; Humans; Incide | 2010 |
Effects of female sex hormones on caffeine-induced epileptiform activity in rats.
Topics: Animals; Caffeine; Corticosterone; Epilepsy; Epinephrine; Estrogen Antagonists; Estrogens; Female; F | 2010 |
Postnatal period of caffeine treatment and time of testing modulate the effect of acute caffeine on cortical epileptic afterdischarges in rats.
Topics: Action Potentials; Aging; Animals; Animals, Newborn; Anticonvulsants; Caffeine; Cerebral Cortex; Con | 2010 |
Caffeine prevents acute mortality after TBI in rats without increased morbidity.
Topics: Animals; Brain Injuries; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Dose-R | 2012 |
The effect of antihistamines on seizures induced by increasing-current electroshocks: ketotifen, but not olopatadine, promotes the seizures in infant rats.
Topics: Age Factors; Animals; Anti-Allergic Agents; Brain; Caffeine; Central Nervous System Stimulants; Dibe | 2012 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons.
Topics: Animals; Anticonvulsants; Caffeine; Calcium; Cells, Cultured; Central Nervous System Stimulants; Ele | 2003 |
[Results with the combined preparation apydan in therapy of symptomatic epilepsy].
Topics: Barbiturates; Bromides; Caffeine; Epilepsy; Humans; Hydantoins | 1956 |
[Epilepsy therapy with the combination preparation centronal compositum].
Topics: Aminopyrine; Caffeine; Epilepsy; Humans; Hydantoins; Phenobarbital; Porphyrins | 1957 |
[Therapeutic effect of Diurex on epilepsy].
Topics: Anticonvulsants; Caffeine; Diuretics; Epilepsy; Salicylates | 1961 |
[GENESIS, CLASSIFICATION AND THERAPY OF LOSS OF CONSCIOUSNESS].
Topics: Caffeine; Child; Classification; Electroencephalography; Epilepsy; Epilepsy, Absence; Humans; Oxyphe | 1963 |
[INCIDENTS IN REID'S INTRACISTERNAL THERAPY WITH PROCAINE-CAFFEINE MIXTURES].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Caffeine; Encephalomyelitis; Epilepsy; Headache; | 1963 |
[TREATMENT OF PATIENTS WITH EPILEPSY WITH FREQUENT PETIT MAL SEIZURES].
Topics: Anticonvulsants; Caffeine; Drug Therapy; Epilepsy; Epilepsy, Absence; Humans; Phenobarbital; Seizure | 1964 |
[THE ANTICONVULSANT ACTIVITY OF ARISAEMA JAPONICUM BL].
Topics: Anticonvulsants; Arisaema; Caffeine; Electric Injuries; Epilepsy; Mice; Pentylenetetrazole; Pharmaco | 1964 |
[Introduction of caffeine in high doses in the treatment of epilepsy. Study of a special aspect of anticonvulsant pharmacotherapy].
Topics: Anticonvulsants; Caffeine; Epilepsy | 1960 |
Caffeine-induced epileptiform field potentials in rat hippocampal slices: a pharmacological characterization.
Topics: 2-Chloroadenosine; Animals; Anticonvulsants; Caffeine; Calcium; Calcium Channel Blockers; Calcium Si | 2004 |
Biphasic effect of chronic postnatal caffeine treatment on cortical epileptic afterdischarges during ontogeny in rats.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Caffeine; Central Nervous System Stimu | 2006 |
Effects of tianeptine on onset time of pentylenetetrazole-induced seizures in mice: possible role of adenosine A1 receptors.
Topics: Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Animals; Anticonvulsants; Antidep | 2007 |
Seizures and hyponatremia after excessive intake of diet coke.
Topics: Aspartame; Caffeine; Carbonated Beverages; Epilepsy; Female; Humans; Hyponatremia; Middle Aged; Wate | 2008 |
[EEG studies of cases with epileptic and intricate somatic manifestations].
Topics: Adult; Asthma; Atropa belladonna; Caffeine; Child; Drug Tolerance; Eczema; Electroencephalography; E | 1967 |
[Legalized koffinautin abuse].
Topics: Caffeine; Epilepsy; Histamine H1 Antagonists; Humans; Hyperkinesis; Psychoses, Substance-Induced; Su | 1981 |
Epileptogenic actions of xanthines in relation to their affinities for adenosine A1 receptors in CA3 neurons of hippocampal slices (guinea pig).
Topics: Adenosine; Animals; Caffeine; Calcium; Cyclic AMP; Epilepsy; Guinea Pigs; Hippocampus; In Vitro Tech | 1994 |
Calcium-antagonistic effects of carbamazepine in epilepsies and affective psychoses.
Topics: Animals; Caffeine; Calcium Channel Blockers; Carbamazepine; Epilepsy; Guinea Pigs; Hippocampus; In V | 1993 |
GABA-responses of CA3 neurones at epileptogenic threshold concentrations of convulsants.
Topics: Action Potentials; Animals; Bicarbonates; Bicuculline; Caffeine; Chlorides; Convulsants; Epilepsy; g | 1993 |
Genetic variation in immediate and delayed postictal refractory period in rats.
Topics: Adenosine; Animals; Caffeine; Central Nervous System Stimulants; Epilepsy; Genetic Variation; Male; | 1996 |
Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats.
Topics: 1-Methyl-3-isobutylxanthine; Acoustic Stimulation; Animals; Caffeine; Convulsants; Dyphylline; Elect | 1997 |
Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants.
Topics: Adult; Anticonvulsants; Caffeine; Carbon Dioxide; Carbon Isotopes; Cytochrome P-450 CYP3A; Cytochrom | 1997 |
Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test.
Topics: Adolescent; Analgesics, Non-Narcotic; Breath Tests; Caffeine; Carbamazepine; Carbon Dioxide; Central | 1998 |
Epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus.
Topics: Action Potentials; Animals; Caffeine; Epilepsy; Hypoxia; Male; Neurons; Rats; Rats, Wistar; Receptor | 1999 |
Relationship between large conductance calcium-activated potassium channel and bursting activity.
Topics: Action Potentials; Animals; Apamin; Caffeine; Calcium; Cells, Cultured; Cerebral Cortex; Epilepsy; I | 2000 |
Influences of caffeine to nitric oxide production and zonisamide concentration in the brain of seizure-susceptible EL mice.
Topics: Animals; Anticonvulsants; Brain; Caffeine; Central Nervous System Stimulants; Drug Interactions; Epi | 2001 |
Effect of orally administered guanosine on seizures and death induced by glutamatergic agents.
Topics: Animals; Brain; Caffeine; Death; Dizocilpine Maleate; Dose-Response Relationship, Drug; Elapid Venom | 2001 |
Psychostimulants and epilepsy.
Topics: Amphetamines; Caffeine; Cannabinoids; Central Nervous System Stimulants; Cocaine; Epilepsy; Hallucin | 2002 |
[Disorders of cerebral hemodynamics and their correction in epilepsy].
Topics: Brain Ischemia; Caffeine; Cerebrovascular Circulation; Epilepsy; Humans; Papaverine; Phenobarbital | 1979 |
[An analysis of 22 years' experience with the medicinal treatment of epilepsy].
Topics: Adult; Anticonvulsants; Bromides; Caffeine; Codeine; Drug Therapy, Combination; Epilepsy; Female; Hi | 1975 |
Paroxysmal activity in the rabbit visual cortex induced by photostimulation.
Topics: Animals; Caffeine; Diazepam; Electroencephalography; Epilepsy; Pentylenetetrazole; Photic Stimulatio | 1991 |
Caffeine-induced epileptic discharges in CA3 neurons of hippocampal slices of the guinea pig.
Topics: Animals; Caffeine; Calcium; Epilepsy; Flunarizine; Guinea Pigs; Hippocampus; In Vitro Techniques; Me | 1991 |
Pregnancy-induced changes in drug metabolism in epileptic women.
Topics: Adult; Anticonvulsants; Biological Availability; Blood Proteins; Caffeine; Chromatography, High Pres | 1991 |
[Changes in cerebral blood circulation and their correction in the interparoxysmal period of epilepsy].
Topics: Adolescent; Adult; Brain Ischemia; Caffeine; Cerebrovascular Circulation; Drug Therapy, Combination; | 1990 |
Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism.
Topics: Adolescent; Adult; Aged; Antipyrine; Caffeine; Carbamazepine; Cytochrome P-450 Enzyme System; Enzyme | 1989 |
Comparative influence of calcium blocker and purinergic drugs on epileptiform bursting in rat hippocampal slices.
Topics: Adenosine; Animals; Caffeine; Calcium; Epilepsy; Hippocampus; In Vitro Techniques; Magnesium; Male; | 1988 |
Modulatory action of purinergic drugs on high potassium-induced epileptiform bursting in rat hippocampal slices.
Topics: Animals; Caffeine; Calcium; Epilepsy; Hippocampus; In Vitro Techniques; Magnesium; Male; Phenylisopr | 1987 |
Protective effect of adenosine and nicotinamide against audiogenic seizure.
Topics: Acoustic Stimulation; Adenosine; Adenosine Triphosphate; Animals; Blood Pressure; Brain Chemistry; C | 1974 |
[Treatment of partial epilepsies with a sultiamum containing combination].
Topics: Adolescent; Adult; Aggression; Anticonvulsants; Barbiturates; Caffeine; Child; Electroencephalograph | 1969 |
Serum copper levels and epilepsy.
Topics: Acetazolamide; Adolescent; Adult; Age Factors; Amphetamine; Anticonvulsants; Caffeine; Ceruloplasmin | 1972 |
[Treatment of epilepsy with a combination of Gardenal and caffeine. Presentation of 84 cases].
Topics: Adolescent; Adult; Caffeine; Epilepsy; Female; Humans; Male; Middle Aged; Phenobarbital | 1968 |
[Treatment of epilepsy using a combination of Gardenal and caffeine. Report of 84 cases].
Topics: Adolescent; Adult; Caffeine; Child; Epilepsy; Female; Humans; Male; Middle Aged; Phenobarbital | 1968 |
[Cessation of status epilepticus and serial seizures with amytal-caffeine].
Topics: Amobarbital; Caffeine; Epilepsy; Humans; Injections, Intravenous; Injections, Subcutaneous | 1970 |
[Therapy of epilepsy].
Topics: Amphetamine; Anticonvulsants; Caffeine; Child; Drug Synergism; Epilepsy; Humans; Hydantoins; Phenoba | 1967 |